Abstract
Reference pricing systems are reimbursement ceilings set by payers in an effort to constrain pharmaceutical expenditure for a private or public drug benefit. In recent years, many governments have adopted reference pricing either as a replacement or in addition to product specific price controls. Programme administrators should consider whether these policies are providing the intended benefits or whether there may be a more effective method.
This article provides a review of reference pricing in Europe, North America and other countries. There are many similarities in the reference price policies but the markets to which they apply are more likely to be different. The European experience gives a ‘once-for-all’ lowering effect on pharmaceutical expenditure, often at the expense of compromises on prescribing. In Germany and The Netherlands, reference pricing has been relatively ineffective in lowering expenditure which has led to a succession of other interventions to achieve expenditure control goals.
The US also has reference pricing, but it occurs in a very competitive market which may be responsible (at least in part) for the relatively modest growth in expenditure compared with European countries. The review of countries with reference pricing policies suggests that such policies are less effective than competitive markets in moderating pharmaceutical expenditure. Nonetheless, governments continue to pursue reference pricing strategies.
Similar content being viewed by others
References
HSU proposals adopted in Sweden. Pharma Pricing Rev 1997;2(2): 27–31
Focus on Central Europe. Pharma Pricing Rev 1997; 2(5): 87–9
Zammit-Lucia J, Dasgupta R. Reference pricing: the Europeanexperience. London: St. Mary’s Hospital Medical School,University of London, 1995. Review paper no.: 10
Spanish HM backing generics. Scrip 1996; 2181: 3
Moen E. Pricing and reimbursement of medicinal products [dissertation]. Oslo: University of Oslo, 1994
Redwood H. The dynamics of drug pricing and reimbursementin the European Community. Felixstowe, England: OldwicksPress, 1992
Redwood H. Pharmapolitics 2000. Felixstowe, England: OldwicksPress, 1997
Therapeutic substitution in Denmark? Pharma Pricing Rev1997; 2(5): 81–3
Denmark: payback deal buys off therapeutic substitution.Pharma Pricing Rev 1998; 3(3): 41–3
Freisler H. Zukunftschance Arzneimittel. Sonderbericht,Mitgliederversammlung des Verbandes Forschender Arzneimittele.V. am 23. January 1997. Bonn: Die PharmazeutischeIndustrie 59(2), II: 43, 1997
Dutch update: PPR interviews ad rietveld of the VWS. Pharma Pricing Rev 1997; 2(3): 41–4
Weinberger CW. Rules and regulation, part 19: limitations onpayment or reimbursement for drugs. Fed Regist 1975; 40(148): 32302
The 1997 Canada Year Book. Ottawa: Statistics Canada, 1997
Pharmacare. Referenced-based pricing policy. Victoria (BC): Pharmacare, 1997
Guidelines for ATC classification. Oslo: WHO CollaboratingCentre for Drug Statistics Methodology, 1990
Operating policies and procedures of Pharmaceutical ManagementAgency Limited. Wellington: Pharmac, 1993
NZ draft medicine tender list out. Scrip 1997; 2274: 14
No ref prices for Australian b-blockers. Scrip 1997; 2274: 14
APMA welcomes ref price exemptions. Scrip 1997; 2289: 19
Australian reference price list out. Scrip 1997; 2276: 16
Spanish reference pricing moves. Scrip 1997; 2280: 3
Reference pricing recommended by Japanese committee. Scrip1997; 2265: 16
Japanese reference pricing criticised. Scrip 1997; 2262: 17
Schwabe U. Überblick ber die Arzneiverordnung im Jahre 1994. In: Schwabe/Paffrath, editors. Arzneiverordnungs-Report‘95. Stuttgart: Gustav Fischer Verlag, 1995
Organisation for Economic Cooperation and Development(OECD) Health Policy Unit. OECD health data 96. Paris: OECD, 1996
Kessler DA, Haas AE, Feiden KL, et al. Approval of new drugsin the US: comparison with the United Kingdom, Germany,and Japan. JAMA 1996; 276(22): 1826–31
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dickson, M., Redwood, H. Pharmaceutical Reference Prices. Pharmacoeconomics 14, 471–479 (1998). https://doi.org/10.2165/00019053-199814050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199814050-00002